Lundbeck Foundation makes hire for new investment department

The foundation, which owns the majority of pharmaceutical firm Lundbeck, has hired Kevin Dalgaard, who comes to the firm from a role in business development at Boehringer Ingelheim.

Photo: Lundbeckfonden / PR

Earlier this year, the Lundbeck Foundation merged its two investment arms Emerge and Ventures together to form Biocapital, which focuses exclusively on early-stage life science startups.

The foundation is now strengthening the team through the hire of Kevin Dalgaard as principal. He comes to the role from a position as strategic partner of business development at Boehringer Ingelheim, where he was also responsible for the German firm’s global licensing activities within cardiovascular disease, metabolic disorders and eye diseases.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs